ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
한센병 치료 시장 규모는 2025년 34억 8,000만 달러에서 2026년부터 2034년까지 CAGR 4.6%로 성장하여 2034년에는 52억 2,000만 달러에 달할 것으로 예측됩니다.
한센병 치료 시장은 공중보건 문제로서의 한센병에 대한 인식이 높아지고 효과적인 치료법에 대한 수요가 증가함에 따라 괄목할만한 성장세를 보이고 있습니다. 세계보건기구(WHO)를 비롯한 국제보건기구가 한센병 퇴치와 의료 접근성 개선에 힘쓰고 있는 가운데, 효과적인 치료법과 관리 전략의 필요성이 급증하고 있습니다. 본 시장에는 주로 다제 병용요법(MDT)을 포함한 다양한 치료법이 포함되어 있으며, MDT는 한센병의 치료와 감염 예방에 효과적임이 입증되었습니다.
또한, 조기 진단과 개입의 중요성이 높아지는 것도 한센병 치료 시장에 영향을 미치고 있습니다. 의료진들이 합병증과 장애를 예방하기 위해 적절한 시기에 치료하는 것이 중요하다는 것을 인식함에 따라, 한센병을 조기에 발견할 수 있는 진단 도구와 스크리닝 프로그램에 대한 수요가 증가하고 있습니다. 이러한 추세에 따라 의료기관은 한센병 치료에 대한 인식 개선과 접근성 향상을 위한 교육 및 자원에 대한 투자를 진행하고 있습니다.
또한, 한센병 치료에 대한 연구개발에 대한 관심이 높아지면서 시장의 혁신을 촉진하고 있습니다. 제약사, 비정부기구, 연구기관 간의 협력은 치료법과 약품의 진보를 주도하고 새로운 제품이 환자의 변화하는 요구에 부응할 수 있도록 보장합니다. 한센병에 대한 사회적 편견에 대한 인식이 높아지고, 치료 지속을 위한 지역사회 지원의 중요성에 대한 이해도 시장 성장에 기여하고 있습니다. 요약하면, 한센병 치료 시장은 치료 옵션의 발전, 조기 개입에 대한 강조, 환자의 치료 성과와 삶의 질 향상에 대한 노력으로 인해 견조한 성장이 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 한센병 치료 시장 : 약물 종류별
제5장 세계의 한센병 치료 시장 : 질환 유형별
제6장 세계의 한센병 치료 시장 : 투여 경로별
제7장 세계의 한센병 치료 시장 : 유통 채널별
제8장 세계의 한센병 치료 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSM
영문 목차
영문목차
The Leprosy Treatment Market size is expected to reach USD 5.22 Billion in 2034 from USD 3.48 Billion (2025) growing at a CAGR of 4.6% during 2026-2034.
The leprosy treatment market is experiencing significant growth, driven by the increasing awareness of leprosy as a public health issue and the rising demand for effective treatment options. As global health organizations work to eliminate leprosy and improve access to care, the need for effective therapies and management strategies is surging. The market includes a range of treatment options, primarily multidrug therapy (MDT), which has proven effective in curing leprosy and preventing its transmission.
Moreover, the growing emphasis on early diagnosis and intervention is influencing the leprosy treatment market. As healthcare providers recognize the importance of timely treatment in preventing complications and disability, there is a rising demand for diagnostic tools and screening programs that facilitate early detection of leprosy. This trend is prompting healthcare organizations to invest in training and resources to improve awareness and access to leprosy care.
Furthermore, the increasing focus on research and development in leprosy treatment is fostering innovation in the market. Collaborations between pharmaceutical companies, non-governmental organizations, and research institutions are driving advancements in treatment methodologies and drug formulations, ensuring that new products meet the evolving needs of patients. The growing awareness of the social stigma associated with leprosy and the importance of community support in treatment adherence is also contributing to market growth. In summary, the leprosy treatment market is set for robust growth, characterized by advancements in treatment options, a focus on early intervention, and a commitment to improving patient outcomes and quality of life.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Drug Class
Antibacterial
Leprostatics
Sulfone
Phenazine
Anti-Tubercular Drugs
Others
By Disease Type
Paucibacillary Leprosy
Multibacillary Leprosy
By Route Of Administration
Oral
Injectable
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
COMPANIES PROFILED
GlaxoSmithKline Pharmaceuticals Ltd, Systopic Laboratories Pvt Ltd, Cadila Pharmaceuticals Corp, Acme Pharmaceuticals, Macleods Pharmaceuticals, Novartis International AG, AstraZeneca Pharma India Ltd, Lark Laboratories India Ltd, Pfizer Inc, BristolMyers Squibb and Company, Eli Lilly and Company, Johnson Johnson Services Inc, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1 Information Analysis
1.3.2 Market Formulation & Data Visualization
1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
3.4.1 Standards & Compliance
3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
3.5.1 Market Drivers
3.5.2 Market Restraints
3.5.3 Market Opportunities
3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. GLOBAL LEPROSY TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)
4.1. Market Analysis, Insights and Forecast Drug Class
4.2. Antibacterial Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Leprostatics Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Sulfone Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Phenazine Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Anti-Tubercular Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL LEPROSY TREATMENT MARKET: BY DISEASE TYPE 2022-2034 (USD MN)
5.1. Market Analysis, Insights and Forecast Disease Type
5.2. Paucibacillary Leprosy Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Multibacillary Leprosy Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL LEPROSY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)
6.1. Market Analysis, Insights and Forecast Route Of Administration
6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL LEPROSY TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
7.1. Market Analysis, Insights and Forecast Distribution Channel
7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL LEPROSY TREATMENT MARKET: BY REGION 2022-2034(USD MN)
8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.2.1 By Drug Class
8.2.2 By Disease Type
8.2.3 By Route Of Administration
8.2.4 By Distribution Channel
8.2.5 United States
8.2.6 Canada
8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.3.1 By Drug Class
8.3.2 By Disease Type
8.3.3 By Route Of Administration
8.3.4 By Distribution Channel
8.3.5 United Kingdom
8.3.6 France
8.3.7 Germany
8.3.8 Italy
8.3.9 Russia
8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.4.1 By Drug Class
8.4.2 By Disease Type
8.4.3 By Route Of Administration
8.4.4 By Distribution Channel
8.4.5 India
8.4.6 Japan
8.4.7 South Korea
8.4.8 Australia
8.4.9 South East Asia
8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.5.1 By Drug Class
8.5.2 By Disease Type
8.5.3 By Route Of Administration
8.5.4 By Distribution Channel
8.5.5 Brazil
8.5.6 Argentina
8.5.7 Peru
8.5.8 Chile
8.5.9 South East Asia
8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.6.1 By Drug Class
8.6.2 By Disease Type
8.6.3 By Route Of Administration
8.6.4 By Distribution Channel
8.6.5 Saudi Arabia
8.6.6 UAE
8.6.7 Israel
8.6.8 South Africa
8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL LEPROSY TREATMENT INDUSTRY
